Pular para o conteúdo
Erros congênitos do metabolismo raros
ORPHA:68367CID-10 · E90DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
heart
Também conhecida comoErros inatos do metabolismoErros metabólicos hereditáriosDoença metabólica rara
Sinônimos clínicos: Doença metabólica rara

Distúrbio hereditário resultante de um defeito enzimático nas vias bioquímicas e metabólicas que afeta o metabolismo de proteínas, gorduras, carboidratos ou função de organelas.

Em construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

Os erros congênitos do metabolismo raros são um conjunto de alterações genéticas em que o corpo apresenta dificuldades para processar substâncias como proteínas, gorduras ou carboidratos. As manifestações catalogadas podem ser bastante diversas, incluindo alterações nos dedos das mãos e pés, problemas na formação dos dentes e impactos no coração ou na visão. Atualmente, esta categoria não possui um PCDT oficial de doenças raras nem medicamentos dispensados pelo SUS em sua lista cadastrada. Por outro lado, diversas pesquisas internacionais e ensaios clínicos seguem em andamento para entender melhor e buscar novas abordagens para essas doenças metabólicas.

📋
Informacoes curadas por IA — podem conter imprecisoes

Distúrbio hereditário resultante de um defeito enzimático nas vias bioquímicas e metabólicas que afeta o metabolismo de proteínas, gorduras, carboidratos ou função de organelas.

Pesquisas ativas
24 ensaios
153 total registrados no ClinicalTrials.gov
Em pesquisa
19 moléculas
IBRUTINIB, PATISIRAN SODIUM, VUTRISIRAN SODIUM

O que está sendo pesquisado

10 moléculas em estudo — nenhuma com registro para esta doença
Ver detalhes e fases →
IBRUTINIBPATISIRAN SODIUMVUTRISIRAN SODIUMSIMVASTATINEZETIMIBEAMLODIPINE BESYLATEPITAVASTATIN CALCIUMALIROCUMAB
Aparecer aqui significa que a molécula foi estudada nesta doença, não que trate. Converse com seu médico.

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
3.3
Germany
🏥
SUS: Sem cobertura SUSScore: 20%
CID-10: E90
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🦴
Ossos e articulações
488 sintomas
🧠
Neurológico
359 sintomas
🫘
Rins
309 sintomas
👁️
Olhos
248 sintomas
💪
Músculos
223 sintomas
🫃
Digestivo
194 sintomas

+ 2633 sintomas em outras categorias

Características mais comuns

—
Hipodontia
—
Hemorragia uterina
—
Anormalidades de segmentação costal
—
Desvio tibial do segundo dedo do pé
—
Incisivos espaçados anormais
—
Sinfalangismo proximal das mãos
5498sintomas
Sem dados (5498)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 5498 características clínicas mais associadas, ordenadas por frequência.

HipodontiaHypodontia
Anormalidades de segmentação costalRib segmentation abnormalities
Desvio tibial do segundo dedo do péTibial deviation of the 2nd toe
Incisivos espaçados anormaisAbnormal spaced incisors

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa10
Últimos 10 anos1publicações
Pico20161 papers
Linha do tempo
20202016Hoje · 2026🧪 1978Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

94 genes identificados com associação a esta condição.

FHFumarate hydratase, mitochondrialDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Citric acid cycle (TCA cycle)Mitochondrial protein degradation
MECANISMO DE DOENÇA

Fumarase deficiency

A severe autosomal recessive metabolic disorder characterized by early-onset hypotonia, profound psychomotor retardation, and brain abnormalities, such as agenesis of the corpus callosum, gyral defects, and ventriculomegaly. Many patients show neonatal distress, metabolic acidosis, and/or encephalopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
139.4 TPM
Fibroblastos
128.8 TPM
Coração - Ventrículo esquerdo
120.5 TPM
Músculo esquelético
115.0 TPM
Fígado
104.5 TPM
OUTRAS DOENÇAS (3)
fumaric aciduriahereditary leiomyomatosis and renal cell cancerhereditary pheochromocytoma-paraganglioma
HGNC:3700UniProt:P07954
SLC25A19Mitochondrial thiamine pyrophosphate carrierCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Vitamin B1 (thiamin) metabolism
MECANISMO DE DOENÇA

Microcephaly, Amish type

A disorder characterized by severe congenital microcephaly and severe 2-ketoglutaric aciduria leading to death within the first year.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
26.8 TPM
Linfócitos
24.0 TPM
Glândula adrenal
9.3 TPM
Baço
9.1 TPM
Nervo tibial
8.8 TPM
OUTRAS DOENÇAS (2)
Amish lethal microcephalyprogressive demyelinating neuropathy with bilateral striatal necrosis
HGNC:14409UniProt:Q9HC21
G6PC1Glucose-6-phosphatase catalytic subunit 1Candidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
GluconeogenesisFOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
MECANISMO DE DOENÇA

Glycogen storage disease 1A

A metabolic disorder characterized by impairment of terminal steps of glycogenolysis and gluconeogenesis. Patients manifest a wide range of clinical symptoms and biochemical abnormalities, including hypoglycemia, severe hepatomegaly due to excessive accumulation of glycogen, kidney enlargement, growth retardation, lactic acidemia, hyperlipidemia, and hyperuricemia.

OUTRAS DOENÇAS (1)
glycogen storage disease due to glucose-6-phosphatase deficiency type IA
HGNC:4056UniProt:P35575
GLB1Beta-galactosidaseCandidate gene tested inTolerante
VIAS BIOLÓGICAS (5)
Sialic acid metabolismGlycosphingolipid catabolismCS/DS degradationKeratan sulfate degradationDefective NEU1 causes sialidosis
MECANISMO DE DOENÇA

GM1-gangliosidosis 1

An autosomal recessive lysosomal storage disease marked by the accumulation of GM1 gangliosides, glycoproteins and keratan sulfate primarily in neurons of the central nervous system. GM1-gangliosidosis type 1 is characterized by onset within the first three months of life, central nervous system degeneration, coarse facial features, hepatosplenomegaly, skeletal dysmorphology reminiscent of Hurler syndrome, and rapidly progressive psychomotor deterioration. Urinary oligosaccharide levels are high. It leads to death usually between the first and second year of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
68.5 TPM
Tireoide
44.2 TPM
Glândula adrenal
40.6 TPM
Cervix Endocervix
35.2 TPM
Pulmão
35.1 TPM
OUTRAS DOENÇAS (4)
mucopolysaccharidosis type 4BGM1 gangliosidosis type 2GM1 gangliosidosis type 3GM1 gangliosidosis type 1
HGNC:4298UniProt:P16278
AASSAlpha-aminoadipic semialdehyde synthase, mitochondrialCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Lysine catabolism
MECANISMO DE DOENÇA

Hyperlysinemia, 1

An autosomal recessive metabolic condition with variable clinical features. Some patients present with non-specific seizures, hypotonia, or mildly delayed psychomotor development, and increased serum lysine and pipecolic acid on laboratory analysis. However, about half of the probands are reported to be asymptomatic, and hyperlysinemia is generally considered to be a benign metabolic variant.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
hyperlysinemiasaccharopinuria
HGNC:17366UniProt:Q9UDR5
DGUOKDeoxyguanosine kinase, mitochondrialCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Purine salvage
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 3

A disorder due to mitochondrial dysfunction characterized by onset in infancy of progressive liver failure, hypoglycemia, increased lactate in body fluids, and neurologic abnormalities including hypotonia, encephalopathy, peripheral neuropathy. Affected tissues show both decreased activity of the mtDNA-encoded respiratory chain complexes and mtDNA depletion.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
78.1 TPM
Pituitária
72.5 TPM
Ovário
63.9 TPM
Aorta
61.4 TPM
Testículo
61.4 TPM
OUTRAS DOENÇAS (3)
mitochondrial DNA depletion syndrome 3 (hepatocerebral type)portal hypertension, noncirrhotic, 1progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4
HGNC:2858UniProt:Q16854
SLC24A5Sodium/potassium/calcium exchanger 5Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Sodium/Calcium exchangers
MECANISMO DE DOENÇA

Albinism, oculocutaneous, 6

A disorder characterized by a reduction or complete loss of melanin in the skin, hair and eyes. Patients show reduced or lacking pigmentation often accompanied by eye symptoms such as photophobia, strabismus, moderate to severe visual impairment, and nystagmus.

EXPRESSÃO TECIDUAL(Não detectado)
Skin Not Sun Exposed Suprapubic
0.3 TPM
Skin Sun Exposed Lower leg
0.3 TPM
Testículo
0.2 TPM
Pituitária
0.1 TPM
Cérebro - Hemisfério cerebelar
0.1 TPM
OUTRAS DOENÇAS (1)
oculocutaneous albinism type 6
HGNC:20611UniProt:Q71RS6
HAMPHepcidinCandidate gene tested inTolerante
MECANISMO DE DOENÇA

Hemochromatosis 2B

A juvenile form of hemochromatosis, a disorder of iron metabolism with excess deposition of iron in a variety of organs leading to their failure, bronze skin pigmentation, hepatic cirrhosis, arthropathy and diabetes. The most common symptoms of juvenile hemochromatosis at presentation are hypogonadism and cardiomyopathy.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
597.3 TPM
Coração - Átrio
133.2 TPM
Brain Spinal cord cervical c-1
16.9 TPM
Pâncreas
4.9 TPM
Hipotálamo
4.8 TPM
OUTRAS DOENÇAS (3)
hemochromatosis type 2Bdigenic hemochromatosishemochromatosis type 2
HGNC:15598UniProt:P81172
SLC25A13Electrogenic aspartate/glutamate antiporter SLC25A13, mitochondrialCandidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
Aspartate and asparagine metabolismMalate-aspartate shuttle
MECANISMO DE DOENÇA

Citrin deficiency, adolescent or adult onset

An autosomal recessive metabolic disorder characterized by elevated serum and urine citrulline levels, ammonia intoxication, and neuropsychiatric symptoms including abnormal behaviors, loss of memory, seizures and coma. Death can result from brain edema.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
44.3 TPM
Brain Spinal cord cervical c-1
21.7 TPM
Skin Sun Exposed Lower leg
21.1 TPM
Cervix Endocervix
19.9 TPM
Glândula adrenal
19.0 TPM
OUTRAS DOENÇAS (3)
citrullinemia, type II, adult-onsetneonatal intrahepatic cholestasis due to citrin deficiencycitrullinemia type II
HGNC:10983UniProt:Q9UJS0
VRK1Serine/threonine-protein kinase VRK1Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Initiation of Nuclear Envelope (NE) Reformation
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1A

A form of pontocerebellar hypoplasia, a disorder characterized by structural defects of the pons and cerebellum, evident upon brain imaging. PCH1A is an autosomal recessive form characterized by an abnormally small cerebellum and brainstem, central and peripheral motor dysfunction from birth, gliosis and spinal cord anterior horn cells degeneration resembling infantile spinal muscular atrophy. Additional features include muscle hypotonia, congenital contractures and respiratory insufficiency that is evident at birth.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
60.6 TPM
Testículo
41.3 TPM
Baço
13.9 TPM
Fibroblastos
12.9 TPM
Fallopian Tube
9.9 TPM
OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, autosomal recessive 10pontocerebellar hypoplasia type 1Apontocerebellar hypoplasia type 1microcephaly-complex motor and sensory axonal neuropathy syndrome
HGNC:12718UniProt:Q99986
EXOSC3Exosome complex component RRP40Candidate gene tested inTolerante
VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1B

A severe autosomal recessive neurologic disorder characterized by a combination of cerebellar and spinal motor neuron degeneration beginning at birth. There is diffuse muscle weakness, progressive microcephaly, global developmental delay, and brainstem involvement.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
30.1 TPM
Testículo
28.1 TPM
Fibroblastos
21.2 TPM
Cervix Endocervix
16.4 TPM
Ovário
15.4 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia type 1Bpontocerebellar hypoplasia type 1
HGNC:17944UniProt:Q9NQT5
EXOSC8Exosome complex component RRP43Candidate gene tested inTolerante
VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1C

A severe autosomal recessive neurodegenerative disease characterized by cerebellar and corpus callosum hypoplasia, abnormal myelination of the central nervous system, and spinal motor neuron disease. Affected individuals manifest failure to thrive, severe muscle weakness, spasticity and psychomotor retardation. Vision and hearing are impaired.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
60.2 TPM
Testículo
43.8 TPM
Ovário
40.4 TPM
Cervix Endocervix
38.1 TPM
Fallopian Tube
37.8 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia, type 1Cpontocerebellar hypoplasia type 1
HGNC:17035UniProt:Q96B26
OATOrnithine aminotransferase, mitochondrialCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Glutamate and glutamine metabolism
MECANISMO DE DOENÇA

Hyperornithinemia with gyrate atrophy of choroid and retina

A disorder clinically characterized by a triad of progressive chorioretinal degeneration, early cataract formation, and type II muscle fiber atrophy. Characteristic chorioretinal atrophy with progressive constriction of the visual fields leads to blindness at the latest during the sixth decade of life. Patients generally have normal intelligence.

EXPRESSÃO TECIDUAL(Ubíquo)
Intestino delgado
165.3 TPM
Fibroblastos
139.5 TPM
Aorta
118.9 TPM
Artéria tibial
116.9 TPM
Cervix Endocervix
110.6 TPM
OUTRAS DOENÇAS (1)
ornithine aminotransferase deficiency
HGNC:8091UniProt:P04181
PRODHProline dehydrogenase 1, mitochondrialCandidate gene tested inDesconhecido
VIAS BIOLÓGICAS (1)
Proline catabolism
MECANISMO DE DOENÇA

Hyperprolinemia 1

An inborn error of proline metabolism resulting in elevated levels of proline in the plasma and urine. The disorder is generally benign and most affected individuals are clinically asymptomatic. Some patients, however, have neurologic manifestations, including epilepsy and intellectual disability. Association with certain forms of schizophrenia have been reported.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
62.7 TPM
Skin Sun Exposed Lower leg
61.6 TPM
Skin Not Sun Exposed Suprapubic
56.9 TPM
Córtex cerebral
50.8 TPM
Brain Anterior cingulate cortex BA24
44.0 TPM
OUTRAS DOENÇAS (2)
hyperprolinemia type 1schizophrenia 4
HGNC:9453UniProt:O43272
GNASProtein ALEXCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (10)
G alpha (s) signalling eventsProstacyclin signalling through prostacyclin receptorADORA2B mediated anti-inflammatory cytokines productionGPER1 signalingG alpha (i) signalling events
EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
1324.4 TPM
Tireoide
727.3 TPM
Hipotálamo
548.6 TPM
Brain Frontal Cortex BA9
501.2 TPM
Cérebro - Hemisfério cerebelar
474.1 TPM
OUTRAS DOENÇAS (12)
progressive osseous heteroplasiapituitary adenoma 3, multiple typespseudohypoparathyroidism type 1CMcCune-Albright syndrome
HGNC:4392UniProt:P84996
L2HGDHL-2-hydroxyglutarate dehydrogenase, mitochondrialCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Interconversion of 2-oxoglutarate and 2-hydroxyglutarate
MECANISMO DE DOENÇA

L-2-hydroxyglutaric aciduria

A rare autosomal recessive disorder clinically characterized by mild psychomotor delay in the first years of life, followed by progressive cerebellar ataxia, dysarthria and moderate to severe intellectual disability. Diagnosis is based on the presence of an excess of L-2-hydroxyglutaric acid in urine, blood and cerebrospinal fluid.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
8.6 TPM
Cérebro - Hemisfério cerebelar
8.3 TPM
Cerebelo
6.8 TPM
Skin Sun Exposed Lower leg
5.3 TPM
Skin Not Sun Exposed Suprapubic
5.2 TPM
OUTRAS DOENÇAS (1)
L-2-hydroxyglutaric aciduria
HGNC:20499UniProt:Q9H9P8
MOCOSMolybdenum cofactor sulfuraseCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Molybdenum cofactor biosynthesis
MECANISMO DE DOENÇA

Xanthinuria 2

A disorder characterized by excretion of very large amounts of xanthine in the urine and a tendency to form xanthine stones. Uric acid is strikingly diminished in serum and urine. In addition, XAN2 patients cannot metabolize allopurinol into oxypurinol due to dual deficiency of xanthine dehydrogenase and aldehyde oxidase.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
14.8 TPM
Ovário
14.3 TPM
Fibroblastos
12.6 TPM
Fígado
11.8 TPM
Esôfago - Mucosa
5.7 TPM
OUTRAS DOENÇAS (1)
xanthinuria type II
HGNC:18234UniProt:Q96EN8
B4GALT1Beta-1,4-galactosyltransferase 1Candidate gene tested inTolerante
VIAS BIOLÓGICAS (4)
Pre-NOTCH Processing in GolgiKeratan sulfate biosynthesisN-Glycan antennae elongationLactose synthesis
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2D

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (2)
combined low LDL and fibrinogenB4GALT1-congenital disorder of glycosylation
HGNC:924UniProt:P15291
RBCK1RanBP-type and C3HC4-type zinc finger-containing protein 1Candidate gene tested inTolerante
VIAS BIOLÓGICAS (4)
Antigen processing: Ubiquitination & Proteasome degradationTNFR1-induced proapoptotic signalingRegulation of TNFR1 signalingTNFR1-induced NF-kappa-B signaling pathway
MECANISMO DE DOENÇA

Polyglucosan body myopathy 1 with or without immunodeficiency

A disease characterized by polyglucosan storage myopathy associated with early-onset progressive muscle weakness and progressive dilated cardiomyopathy, which may necessitate cardiac transplant in severe cases. Some patients present with severe immunodeficiency, invasive bacterial infections and chronic autoinflammation.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
135.7 TPM
Cérebro - Hemisfério cerebelar
126.4 TPM
Pituitária
116.3 TPM
Baço
102.0 TPM
Tireoide
101.6 TPM
OUTRAS DOENÇAS (2)
polyglucosan body myopathy 1 with or without immunodeficiencyautoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis
HGNC:15864UniProt:Q9BYM8
VPS33AVacuolar protein sorting-associated protein 33ACandidate gene tested inRestrito
VIAS BIOLÓGICAS (1)
SARS-CoV-2 modulates autophagy
MECANISMO DE DOENÇA

Mucopolysaccharidosis-plus syndrome

A form of mucopolysaccharidosis, a group of lysosomal storage diseases characterized by defective degradation of glycosaminoglycans, resulting in their excessive accumulation and secretion. The diseases are progressive and often display a wide spectrum of clinical severity. MPSPS is an autosomal recessive form characterized by coarse facial features, dysostosis multiplex, hepatosplenomegaly, respiratory difficulties, intellectual disability, developmental delay, pyramidal signs, severe chronic anemia, renal involvement and cardiac defects. Laboratory analyses show proteinuria with glomerular foamy cells, excess secretion of urinary glycosaminoglycans, and extremely high levels of plasma heparan sulphate. Disease onset is in infancy. Most patients die in the first years of life due to cardiorespiratory failure.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
25.3 TPM
Pituitária
17.0 TPM
Linfócitos
15.2 TPM
Cérebro - Hemisfério cerebelar
14.8 TPM
Fibroblastos
14.1 TPM
OUTRAS DOENÇAS (1)
mucopolysaccharidosis-plus syndrome
HGNC:18179UniProt:Q96AX1
MT-ATP6ATP synthase F(0) complex subunit aCandidate gene tested inDesconhecido
VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationFormation of ATP by chemiosmotic couplingCristae formationMitochondrial protein degradation
MECANISMO DE DOENÇA

Neuropathy, ataxia, and retinitis pigmentosa

A syndrome characterized by variable combination of developmental delay, psychomotor retardation, hearing loss, optic atrophy and retinitis pigmentosa, dementia, seizures, ataxia, proximal neurogenic muscle weakness, and sensory neuropathy.

OUTRAS DOENÇAS (8)
mitochondrial diseasematernally-inherited Leigh syndromefamilial infantile bilateral striatal necrosismitochondrial proton-transporting ATP synthase complex deficiency
HGNC:7414UniProt:P00846
MT-TL1Candidate gene tested inDesconhecido
VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (7)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndromeMERRF syndrome
HGNC:7490
MT-ND4NADH-ubiquinone oxidoreductase chain 4Candidate gene tested inDesconhecido
VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial translation termination
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (6)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndromeLeber plus disease
HGNC:7459UniProt:P03905
SUGCTSuccinyl-CoA:glutarate CoA-transferaseCandidate gene tested inTolerante
MECANISMO DE DOENÇA

Glutaric aciduria 3

An autosomal recessive metabolic condition characterized by urinary excretion of abnormal quantities of glutaric acid, in the presence of normal 3-hydroxyglutarate, glutarylcarnitine and glutarylglycine urinary levels. Affected individuals show no consistent clinical phenotype and many are asymptomatic.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
26.0 TPM
Artéria coronária
15.9 TPM
Fibroblastos
15.3 TPM
Glândula adrenal
14.8 TPM
Artéria tibial
9.7 TPM
OUTRAS DOENÇAS (1)
glutaric acidemia type 3
HGNC:16001UniProt:Q9HAC7
KYNUKynureninaseCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Tryptophan catabolism
MECANISMO DE DOENÇA

Hydroxykynureninuria

An inborn error of amino acid metabolism characterized by massive urinary excretion of large amounts of kynurenine, 3-hydroxykynurenine and xanthurenic acid. Affected individuals manifest renal tubular dysfunction, metabolic acidosis, psychomotor retardation, non-progressive encephalopathy, and muscular hypertonia.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
6.9 TPM
Fígado
3.7 TPM
Testículo
2.6 TPM
Pulmão
2.2 TPM
Baço
1.9 TPM
OUTRAS DOENÇAS (3)
vertebral, cardiac, renal, and limb defects syndrome 2encephalopathy due to hydroxykynureninuriacongenital vertebral-cardiac-renal anomalies syndrome
HGNC:6469UniProt:Q16719
DHTKD12-oxoadipate dehydrogenase complex component E1Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
OADH complex synthesizes glutaryl-CoA from 2-OA
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2Q

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
51.2 TPM
Linfócitos
43.7 TPM
Ovário
22.0 TPM
Nervo tibial
17.9 TPM
Tireoide
17.1 TPM
OUTRAS DOENÇAS (2)
Charcot-Marie-Tooth disease axonal type 2Q2-aminoadipic 2-oxoadipic aciduria
HGNC:23537UniProt:Q96HY7
IDUAAlpha-L-iduronidaseCandidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
CS/DS degradationHS-GAG degradation
MECANISMO DE DOENÇA

Mucopolysaccharidosis 1H

A severe form of mucopolysaccharidosis type 1, a rare lysosomal storage disease characterized by progressive physical deterioration with urinary excretion of dermatan sulfate and heparan sulfate. Patients with MPS1H usually present, within the first year of life, a combination of hepatosplenomegaly, skeletal deformities, corneal clouding and severe intellectual disability. Obstructive airways disease, respiratory infection and cardiac complications usually result in death before 10 years of age.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
72.3 TPM
Cérebro - Hemisfério cerebelar
53.9 TPM
Cervix Endocervix
44.9 TPM
Tireoide
37.9 TPM
Útero
37.1 TPM
OUTRAS DOENÇAS (4)
Hurler-Scheie syndromeHurler syndromeScheie syndromemucopolysaccharidosis type 1
HGNC:5391UniProt:P35475
ALPLAlkaline phosphatase, tissue-nonspecific isozymeCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Post-translational modification: synthesis of GPI-anchored proteins
MECANISMO DE DOENÇA

Hypophosphatasia

A metabolic bone disease characterized by defective skeletal mineralization and biochemically by deficient activity of the tissue non-specific isoenzyme of alkaline phosphatase. Four forms are distinguished, depending on the age of onset: perinatal, infantile, childhood and adult type. The perinatal form is the most severe and is almost always fatal. The adult form is mild and characterized by recurrent fractures, osteomalacia, rickets, and loss of teeth. Some cases are asymptomatic, while some patients manifest dental features without skeletal manifestations (odontohypophosphatasia).

OUTRAS DOENÇAS (5)
adult hypophosphatasiainfantile hypophosphatasiachildhood hypophosphatasiaperinatal lethal hypophosphatasia
HGNC:438UniProt:P05186
ABCC8ATP-binding cassette sub-family C member 8Candidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
Regulation of insulin secretionATP sensitive Potassium channels
MECANISMO DE DOENÇA

Leucine-induced hypoglycemia

Rare cause of hypoglycemia and is described as a condition in which symptomatic hypoglycemia is provoked by high protein feedings. Hypoglycemia is also elicited by administration of oral or intravenous infusions of a single amino acid, leucine.

OUTRAS DOENÇAS (12)
hyperinsulinemic hypoglycemia, familial, 1diabetes mellitus, transient neonatal, 2diabetes mellitus, permanent neonatal 3hypoglycemia, leucine-induced
HGNC:59UniProt:Q09428
PSENENGamma-secretase subunit PEN-2Candidate gene tested inRestrito
VIAS BIOLÓGICAS (10)
Activated NOTCH1 Transmits Signal to the NucleusNOTCH3 Activation and Transmission of Signal to the NucleusNOTCH4 Activation and Transmission of Signal to the NucleusNoncanonical activation of NOTCH3NOTCH2 Activation and Transmission of Signal to the Nucleus
MECANISMO DE DOENÇA

Acne inversa, familial, 2, with or without Dowling-Degos disease

An autosomal dominant form of acne inversa, a chronic relapsing inflammatory disease of the hair follicles characterized by recurrent draining sinuses, painful skin abscesses, and disfiguring scars. Manifestations typically appear after puberty. Some ACNINV2 patients also exhibit reticulate hyperpigmentation consistent with Dowling-Degos disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
189.4 TPM
Tireoide
64.5 TPM
Cervix Endocervix
59.0 TPM
Pituitária
56.5 TPM
Sangue
55.5 TPM
OUTRAS DOENÇAS (2)
acne inversa, familial, 2Dowling-Degos disease
HGNC:30100UniProt:Q9NZ42
VMA22Vacuolar ATPase assembly protein VMA22Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
RHOA GTPase cycle
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2O

A form of congenital disorder of glycosylation, a genetically heterogeneous group of autosomal recessive, multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG2O is characterized by hepatosplenomegaly, liver failure, hypotonia, and psychomotor disability.

VIAS REACTOME (1)
OUTRAS DOENÇAS (1)
CCDC115-CDG
HGNC:28178UniProt:Q96NT0
ALDH18A1Delta-1-pyrroline-5-carboxylate synthaseCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Mitochondrial protein degradation
MECANISMO DE DOENÇA

Cutis laxa, autosomal recessive, 3A

A syndrome characterized by facial dysmorphism with a progeroid appearance, large and late-closing fontanel, cutis laxa, joint hyperlaxity, athetoid movements and hyperreflexia, pre- and postnatal growth retardation, intellectual deficit, developmental delay, and ophthalmologic abnormalities.

OUTRAS DOENÇAS (6)
hereditary spastic paraplegia 9Aautosomal recessive complex spastic paraplegia type 9Bcutis laxa, autosomal dominant 3ALDH18A1-related de Barsy syndrome
HGNC:9722UniProt:P54886
QRSL1Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrialCandidate gene tested inTolerante
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 40

An autosomal recessive mitochondrial disorder characterized by prenatal or infantile onset, fetal hydrops, severe hypertrophic cardiomyopathy, poor growth, sensorineural hearing loss, hepatic dysfunction, lactic acidosis, and decreased activities of mitochondrial respiratory complexes I, III, IV, and V. The disorder is lethal, with death occurring in infancy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
17.2 TPM
Baço
12.2 TPM
Nervo tibial
10.9 TPM
Músculo esquelético
10.6 TPM
Fibroblastos
10.5 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation deficiency 40
HGNC:21020UniProt:Q9H0R6
MRPL3Large ribosomal subunit protein uL3mCandidate gene tested inTolerante
VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationMitochondrial ribosome-associated quality controlMitochondrial translation initiationMitochondrial translation elongation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 9

A mitochondrial disease characterized by failure to thrive, poor feeding, hypertrophic cardiomyopathy, hepatomegaly, and psychomotor retardation. Death in infancy has been observed in some cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
147.1 TPM
Fibroblastos
142.8 TPM
Testículo
72.3 TPM
Tireoide
70.7 TPM
Ovário
69.2 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation defect type 9
HGNC:10379UniProt:P09001
AARS2Alanine--tRNA ligase, mitochondrialCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 8

A mitochondrial disease characterized by a lethal infantile hypertrophic cardiomyopathy, generalized muscle dysfunction and some neurologic involvement. The liver is not affected.

OUTRAS DOENÇAS (4)
leukoencephalopathy, progressive, with ovarian failurecombined oxidative phosphorylation defect type 8leukoencephalopathy, diffuse hereditary, with spheroids 1obsolete ovarioleukodystrophy
HGNC:21022UniProt:Q5JTZ9
ABAT4-aminobutyrate aminotransferase, mitochondrialCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Degradation of GABA
MECANISMO DE DOENÇA

GABA-transaminase deficiency

An enzymatic deficiency resulting in psychomotor retardation, hypotonia, hyperreflexia, lethargy, refractory seizures, and EEG abnormalities. GABATD inheritance is autosomal recessive.

VIAS REACTOME (1)
OUTRAS DOENÇAS (1)
GABA aminotransaminase deficiency
HGNC:23UniProt:P80404
MCCC1Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrialCandidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
Defective HLCS causes multiple carboxylase deficiencyBiotin transport and metabolism
MECANISMO DE DOENÇA

3-methylcrotonoyl-CoA carboxylase 1 deficiency

An autosomal recessive disorder of leucine catabolism. The phenotype is variable, ranging from neonatal onset with severe neurological involvement to asymptomatic adults. There is a characteristic organic aciduria with massive excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine, usually in combination with a severe secondary carnitine deficiency.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.9 TPM
Ovário
28.1 TPM
Glândula adrenal
26.9 TPM
Tireoide
25.8 TPM
Nervo tibial
25.6 TPM
OUTRAS DOENÇAS (2)
3-methylcrotonyl-CoA carboxylase 1 deficiency3-methylcrotonyl-CoA carboxylase deficiency
HGNC:6936UniProt:Q96RQ3
GM2AGanglioside GM2 activatorCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

GM2-gangliosidosis AB

An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the presence of both normal hexosaminidase A and B.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
105.2 TPM
Vagina
90.7 TPM
Skin Not Sun Exposed Suprapubic
85.3 TPM
Skin Sun Exposed Lower leg
78.9 TPM
Esôfago - Mucosa
77.5 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (1)
Tay-Sachs disease AB variant
HGNC:4367UniProt:P17900
MT-ND1NADH-ubiquinone oxidoreductase chain 1Candidate gene tested inDesconhecido
VIAS BIOLÓGICAS (4)
Respiratory electron transportComplex I biogenesisMitochondrial translation terminationMitochondrial protein degradation
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (5)
mitochondrial diseaseMELAS syndromemitochondrial complex I deficiencymaternally-inherited Leigh syndrome
HGNC:7455UniProt:P03886
MT-TFCandidate gene tested inDesconhecido
VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
OUTRAS DOENÇAS (4)
mitochondrial diseaseMELAS syndromeGitelman-like kidney tubulopathy due to mitochondrial DNA mutationMERRF syndrome
HGNC:7481
POLG2DNA polymerase subunit gamma-2Candidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
Strand-asynchronous mitochondrial DNA replicationTranscriptional activation of mitochondrial biogenesis
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 4

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
30.1 TPM
Ovário
22.2 TPM
Linfócitos
19.3 TPM
Cervix Endocervix
18.3 TPM
Útero
16.6 TPM
OUTRAS DOENÇAS (4)
progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4mitochondrial DNA depletion syndrome 16 (hepatic type)mitochondrial dna depletion syndrome 16B (neuroophthalmic type)autosomal dominant progressive external ophthalmoplegia
HGNC:9180UniProt:Q9UHN1
MT-THCandidate gene tested inDesconhecido
VIAS BIOLÓGICAS (1)
Catecholamine biosynthesis
OUTRAS DOENÇAS (4)
mitochondrial diseaseMERRF syndromeMELAS syndromemitochondrial non-syndromic sensorineural hearing loss
HGNC:7487
MT-TS1Candidate gene tested inDesconhecido
VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (6)
mitochondrial diseaseMERRF syndromepalmoplantar keratoderma-deafness syndromematernally-inherited progressive external ophthalmoplegia
HGNC:7497
INSInsulinCandidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
Insulin receptor recyclingSignaling by Insulin receptor
MECANISMO DE DOENÇA

Hyperproinsulinemia

An autosomal dominant condition characterized by elevated levels of serum proinsulin-like material.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pâncreas
2325.3 TPM
Glândula adrenal
0.5 TPM
Cervix Ectocervix
0.5 TPM
Substância negra
0.4 TPM
Baço
0.3 TPM
OUTRAS DOENÇAS (6)
maturity-onset diabetes of the young type 10diabetes mellitus, permanent neonatal 4hyperproinsulinemiatype 1 diabetes mellitus 2
HGNC:6081UniProt:P01308
POLGDNA polymerase subunit gamma-1Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Strand-asynchronous mitochondrial DNA replication
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 1

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
48.3 TPM
Linfócitos
42.0 TPM
Baço
41.5 TPM
Útero
40.9 TPM
Pulmão
38.7 TPM
OUTRAS DOENÇAS (11)
sensory ataxic neuropathy, dysarthria, and ophthalmoparesismitochondrial DNA depletion syndrome 4bmitochondrial DNA depletion syndrome 4amitochondrial disease
HGNC:9179UniProt:P54098
IDSIduronate 2-sulfataseCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (2)
MPS II - Hunter syndrome (CS/DS degradation)MPS II - Hunter syndrome (HS-GAG degradation)
MECANISMO DE DOENÇA

Mucopolysaccharidosis 2

An X-linked lysosomal storage disease characterized by intracellular accumulation of heparan sulfate and dermatan sulfate and their excretion in urine. Most children with MPS2 have a severe form with early somatic abnormalities including skeletal deformities, hepatosplenomegaly, and progressive cardiopulmonary deterioration. A prominent feature is neurological damage that presents as developmental delay and hyperactivity but progresses to intellectual disability and dementia. They die before 15 years of age, usually as a result of obstructive airway disease or cardiac failure. In contrast, those with a mild form of MPS2 may survive into adulthood, with attenuated somatic complications and often without intellectual disability.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Anterior cingulate cortex BA24
427.4 TPM
Brain Frontal Cortex BA9
413.8 TPM
Córtex cerebral
282.6 TPM
Brain Nucleus accumbens basal ganglia
262.1 TPM
Cérebro - Amígdala
242.7 TPM
OUTRAS DOENÇAS (3)
mucopolysaccharidosis type 2mucopolysaccharidosis type 2, severe formmucopolysaccharidosis type 2, attenuated form
HGNC:5389UniProt:P22304
PEX1Peroxisomal ATPase PEX1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Peroxisomal protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 1

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
23.8 TPM
Nervo tibial
23.3 TPM
Cervix Endocervix
23.1 TPM
Tireoide
21.9 TPM
Cerebelo
21.8 TPM
OUTRAS DOENÇAS (6)
peroxisome biogenesis disorder 1Bperoxisome biogenesis disorder 1A (Zellweger)peroxisome biogenesis disorder due to PEX1 defectZellweger spectrum disorders
HGNC:8850UniProt:O43933
SQSTM1Sequestosome-1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (9)
PINK1-PRKN Mediated MitophagyPexophagyNF-kB is activated and signals survivalp75NTR recruits signalling complexesInterleukin-1 signaling
MECANISMO DE DOENÇA

Paget disease of bone 3

A disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
155.2 TPM
Artéria tibial
140.4 TPM
Aorta
135.6 TPM
Fibroblastos
134.0 TPM
Glândula adrenal
131.3 TPM
OUTRAS DOENÇAS (8)
Paget disease of bone 3myopathy, distal, with rimmed vacuolesneurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onsetfrontotemporal dementia and/or amyotrophic lateral sclerosis 3
HGNC:11280UniProt:Q13501
AFG3L2Mitochondrial inner membrane m-AAA protease component AFG3L2Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Processing of SMDT1Mitochondrial protein degradation
MECANISMO DE DOENÇA

Spinocerebellar ataxia 28

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA28 is an autosomal dominant cerebellar ataxia (ADCA) with a slow progressive course and no evidence of sensory involvement or cognitive impairment.

OUTRAS DOENÇAS (3)
optic atrophy 12spinocerebellar ataxia type 28spastic ataxia 5
HGNC:315UniProt:Q9Y4W6
NPC1NPC intracellular cholesterol transporter 1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
LDL clearance
MECANISMO DE DOENÇA

Niemann-Pick disease C1

A lysosomal storage disorder that affects the viscera and the central nervous system. It is due to defective intracellular processing and transport of low-density lipoprotein derived cholesterol. It causes accumulation of cholesterol in lysosomes, with delayed induction of cholesterol homeostatic reactions. Niemann-Pick disease type C1 has a highly variable clinical phenotype. Clinical features include variable hepatosplenomegaly and severe progressive neurological dysfunction such as ataxia, dystonia and dementia. The age of onset can vary from infancy to late adulthood. An allelic variant of Niemann-Pick disease type C1 is found in people with Nova Scotia ancestry. Patients with the Nova Scotian clinical variant are less severely affected.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
39.4 TPM
Fibroblastos
32.1 TPM
Glândula adrenal
31.5 TPM
Pulmão
30.3 TPM
Nervo tibial
24.6 TPM
OUTRAS DOENÇAS (6)
Niemann-Pick disease, type C1Niemann-Pick disease type C, late infantile neurologic onsetNiemann-Pick disease type C, juvenile neurologic onsetNiemann-Pick disease type C, severe perinatal form
HGNC:7897UniProt:O15118
SMPD1Sphingomyelin phosphodiesteraseDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Niemann-Pick disease A

An early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, intellectual disability, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
79.4 TPM
Tireoide
67.2 TPM
Pituitária
65.9 TPM
Aorta
63.0 TPM
Cerebelo
61.4 TPM
OUTRAS DOENÇAS (2)
Niemann-Pick disease type BNiemann-Pick disease type A
HGNC:11120UniProt:P17405
COASYBifunctional coenzyme A synthaseDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Coenzyme A biosynthesis
MECANISMO DE DOENÇA

Neurodegeneration with brain iron accumulation 6

A neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. It is characterized by progressive motor and cognitive dysfunction beginning in childhood or young adulthood. Patients show extrapyramidal motor signs, such as spasticity, dystonia, and parkinsonism.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
neurodegeneration with brain iron accumulation 6pontocerebellar hypoplasia, type 12
HGNC:29932UniProt:Q13057
FTLFerritin light chainDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Scavenging by Class A ReceptorsNeutrophil degranulation
MECANISMO DE DOENÇA

Hyperferritinemia with or without cataract

An autosomal dominant disease characterized by elevated level of ferritin in serum and tissues, and early-onset bilateral cataract. Cataracts may be subclinical in some patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
13154.6 TPM
Fibroblastos
12572.4 TPM
Pulmão
12131.1 TPM
Tecido adiposo
10012.1 TPM
Baço
9808.3 TPM
OUTRAS DOENÇAS (4)
neuroferritinopathyL-ferritin deficiencyhereditary hyperferritinemia with congenital cataractsobsolete genetic hyperferritinemia without iron overload
HGNC:3999UniProt:P02792
PHGDHD-3-phosphoglycerate dehydrogenaseDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Serine metabolism
MECANISMO DE DOENÇA

Phosphoglycerate dehydrogenase deficiency

An autosomal recessive inborn error of L-serine biosynthesis, clinically characterized by congenital microcephaly, psychomotor retardation, and seizures.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
83.1 TPM
Brain Spinal cord cervical c-1
50.3 TPM
Skin Not Sun Exposed Suprapubic
50.0 TPM
Glândula salivar
47.9 TPM
Testículo
45.6 TPM
OUTRAS DOENÇAS (2)
Neu-Laxova syndrome 1PHGDH deficiency
HGNC:8923UniProt:O43175
EPM2ALaforin, isoform 9Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Glycogen synthesisMyoclonic epilepsy of Lafora
EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
21.7 TPM
Cólon sigmoide
17.6 TPM
Esôfago - Muscular
16.6 TPM
Esôfago - Junção
14.9 TPM
Brain Spinal cord cervical c-1
13.9 TPM
OUTRAS DOENÇAS (2)
myoclonic epilepsy of Lafora 1Lafora disease
HGNC:3413UniProt:B3EWF7
ALG2Alpha-1,3/1,6-mannosyltransferase ALG2Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
OUTRAS DOENÇAS (3)
congenital myasthenic syndrome 14ALG2-congenital disorder of glycosylationobsolete congenital myasthenic syndromes with glycosylation defect
HGNC:23159UniProt:Q9H553
DAG1Dystroglycan 1Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy limb-girdle C9

An autosomal recessive muscular dystrophy showing onset in early childhood, and associated with intellectual disability without structural brain anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
118.7 TPM
Artéria tibial
71.1 TPM
Aorta
69.5 TPM
Esôfago - Muscular
66.9 TPM
Esôfago - Junção
64.7 TPM
OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Pmuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A9isolated asymptomatic elevation of creatine phosphokinasemuscular dystrophy-dystroglycanopathy, type A
HGNC:2666UniProt:Q14118
PHKA1Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoformDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Glycogen breakdown (glycogenolysis)
MECANISMO DE DOENÇA

Glycogen storage disease 9D

A metabolic disorder characterized by slowly progressive, predominantly distal muscle weakness and atrophy. Clinical features include exercise intolerance with early fatigability, pain, cramps and occasionally myoglobinuria.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
65.5 TPM
Glândula adrenal
24.4 TPM
Pituitária
20.2 TPM
Ovário
17.4 TPM
Aorta
17.3 TPM
OUTRAS DOENÇAS (1)
glycogen storage disease IXd
HGNC:8925UniProt:P46020
SUMF1Formylglycine-generating enzymeDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
The activation of arylsulfatasesGlycosphingolipid catabolism
MECANISMO DE DOENÇA

Multiple sulfatase deficiency

A clinically and biochemically heterogeneous disorder caused by the simultaneous impairment of all sulfatases, due to defective post-translational modification and activation. It combines features of individual sulfatase deficiencies such as metachromatic leukodystrophy, mucopolysaccharidosis, chondrodysplasia punctata, hydrocephalus, ichthyosis, neurologic deterioration and developmental delay.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
20.9 TPM
Aorta
17.9 TPM
Tireoide
16.0 TPM
Artéria coronária
14.4 TPM
Esôfago - Mucosa
13.6 TPM
OUTRAS DOENÇAS (1)
mucosulfatidosis
HGNC:20376UniProt:Q8NBK3
PIGTGPI-anchor transamidase component PIGTDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Attachment of GPI anchor to uPAR
MECANISMO DE DOENÇA

Multiple congenital anomalies-hypotonia-seizures syndrome 3

An autosomal recessive syndrome characterized by distinct facial features, intellectual disability, hypotonia and seizures, in combination with abnormal skeletal, endocrine, and ophthalmologic findings including impaired vision, as well as abnormal motility of the eyes.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
53.6 TPM
Artéria coronária
42.9 TPM
Artéria tibial
38.8 TPM
Útero
35.9 TPM
Fibroblastos
35.5 TPM
OUTRAS DOENÇAS (2)
multiple congenital anomalies-hypotonia-seizures syndrome 3paroxysmal nocturnal hemoglobinuria 2
HGNC:14938UniProt:Q969N2
HGSNATHeparan-alpha-glucosaminide N-acetyltransferaseDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
HS-GAG degradation
MECANISMO DE DOENÇA

Mucopolysaccharidosis 3C

A form of mucopolysaccharidosis type 3, an autosomal recessive lysosomal storage disease due to impaired degradation of heparan sulfate. MPS3 is characterized by severe central nervous system degeneration, but only mild somatic disease. Onset of clinical features usually occurs between 2 and 6 years; severe neurologic degeneration occurs in most patients between 6 and 10 years of age, and death occurs typically during the second or third decade of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
80.4 TPM
Cervix Ectocervix
76.1 TPM
Ovário
71.9 TPM
Nervo tibial
67.3 TPM
Útero
66.7 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (3)
mucopolysaccharidosis type 3Cretinitis pigmentosa 73retinitis pigmentosa
HGNC:26527UniProt:Q68CP4
GUSBBeta-glucuronidaseDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
CS/DS degradationHyaluronan degradation
MECANISMO DE DOENÇA

Mucopolysaccharidosis 7

A form of mucopolysaccharidosis, a group of lysosomal storage diseases characterized by defective degradation of glycosaminoglycans, resulting in their excessive accumulation and secretion. The diseases are progressive and often display a wide spectrum of clinical severity. MPS7 is an autosomal recessive form with a highly variable phenotype, ranging from severe lethal hydrops fetalis to mild forms with survival into adulthood. Most patients with the intermediate phenotype show hepatomegaly, skeletal anomalies, coarse facies, and variable degrees of mental impairment.

EXPRESSÃO TECIDUAL(Ubíquo)
Baço
87.0 TPM
Pulmão
72.5 TPM
Tireoide
72.5 TPM
Nervo tibial
69.4 TPM
Ovário
67.2 TPM
OUTRAS DOENÇAS (1)
mucopolysaccharidosis type 7
HGNC:4696UniProt:P08236
COX6B1Cytochrome c oxidase subunit 6B1Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (4)
Cytoprotection by HMOX1Respiratory electron transportTP53 Regulates Metabolic GenesComplex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 7

An autosomal recessive mitochondrial disorder characterized by encephalomyopathy resulting in variable clinical manifestations. Features include muscle weakness, gait disturbances, neurodegeneration, cognitive decline, metabolic acidosis, feeding difficulties, poor overall growth, cortical visual impairment, and hypertrophic cardiomyopathy. Serum lactate levels are increased. Patient tissues show decreased levels and activity of mitochondrial respiratory complex IV.

OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 7mitochondrial complex IV deficiency, nuclear-type
HGNC:2280UniProt:P14854
COX10Protoheme IX farnesyltransferase, mitochondrialDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Heme biosynthesis
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 3

An autosomal recessive mitochondrial disorder characterized by cytochrome c oxidase deficiency. Clinical features include muscle weakness, hypotonia, ataxia, ptosis, metabolic acidosis, poor feeding, delayed motor development, anemia, sensorineural hearing loss, and cardiomyopathy.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 3mitochondrial complex IV deficiency, nuclear-type
HGNC:2260UniProt:Q12887
SURF1Surfeit locus protein 1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Complex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 1

An autosomal recessive disorder of the mitochondrial respiratory chain characterized by early-onset, rapidly progressive encephalopathy, neurodegeneration, and loss of motor and cognitive skills. Affected individuals show hypotonia, failure to thrive, loss of the ability to sit or walk, poor communication, poor eye contact, oculomotor abnormalities, as well as deafness, ataxia, tremor, and brisk tendon reflexes. Brain imaging shows bilateral symmetric lesions in the basal ganglia. Lactate levels in serum and cerebrospinal fluid are increased. Patient tissues show decreased levels and activity of mitochondrial respiratory complex IV. Death in childhood may occur, often due to central respiratory failure.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
67.2 TPM
Artéria tibial
65.0 TPM
Aorta
63.9 TPM
Cólon sigmoide
62.4 TPM
Esôfago - Junção
60.0 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 1Charcot-Marie-Tooth disease type 4K
HGNC:11474UniProt:Q15526
SDHASuccinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrialDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Maturation of TCA enzymes and regulation of TCA cycle
MECANISMO DE DOENÇA

Mitochondrial complex II deficiency, nuclear type 1

A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations. Clinical features include psychomotor regression in infants, poor growth with lack of speech development, severe spastic quadriplegia, dystonia, progressive leukoencephalopathy, muscle weakness, exercise intolerance, cardiomyopathy. Some patients manifest Leigh syndrome or Kearns-Sayre syndrome. MC2DN1 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
302.0 TPM
Músculo esquelético
237.6 TPM
Coração - Átrio
206.8 TPM
Glândula adrenal
172.2 TPM
Linfócitos
168.3 TPM
OUTRAS DOENÇAS (9)
mitochondrial complex II deficiency, nuclear type 1pheochromocytoma/paraganglioma syndrome 5neurodegeneration with ataxia and late-onset optic atrophydilated cardiomyopathy 1GG
HGNC:10680UniProt:P31040
NDUFS2NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 6

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN6 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
154.5 TPM
Ovário
130.0 TPM
Cérebro - Hemisfério cerebelar
124.7 TPM
Coração - Ventrículo esquerdo
120.8 TPM
Cerebelo
120.6 TPM
OUTRAS DOENÇAS (4)
mitochondrial complex I deficiency, nuclear type 6Leber-like hereditary optic neuropathy, autosomal recessive 2mitochondrial complex I deficiencyLeber hereditary optic neuropathy
HGNC:7708UniProt:O75306
NDUFA8NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 37

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN37 features include developmental delay, cerebral atrophy, epilepsy, growth retardation, congenital myopathy with disproportion of fibers, and severely decreased activity of complex I. MC1DN37 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
220.3 TPM
Coração - Átrio
208.0 TPM
Testículo
204.3 TPM
Brain Frontal Cortex BA9
172.0 TPM
Cólon sigmoide
162.4 TPM
OUTRAS DOENÇAS (1)
mitochondrial complex I deficiency, nuclear type 37
HGNC:HGNC:7692UniProt:P51970
NDUFAF6NADH dehydrogenase (ubiquinone) complex I, assembly factor 6Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Complex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 17

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN17 transmission pattern is consistent with autosomal recessive inheritance.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
7.9 TPM
Tireoide
7.7 TPM
Testículo
7.2 TPM
Nervo tibial
7.0 TPM
Cerebelo
6.5 TPM
OUTRAS DOENÇAS (3)
mitochondrial complex I deficiency, nuclear type 17Fanconi renotubular syndrome 5primary Fanconi syndrome
HGNC:28625UniProt:Q330K2
MRM2rRNA methyltransferase 2, mitochondrialDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
rRNA modification in the mitochondrion
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 17

An autosomal recessive mitochondrial disorder characterized by childhood onset of rapidly progressive encephalopathy, stroke-like episodes, lactic acidosis, hypocitrullinemia, multiple defects of oxidative phosphorylation, mitochondrial complex I and IV deficiency, and reduced mtDNA copy number.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
49.9 TPM
Fibroblastos
31.2 TPM
Baço
22.1 TPM
Útero
20.5 TPM
Testículo
20.4 TPM
OUTRAS DOENÇAS (1)
mitochondrial DNA depletion syndrome 17
HGNC:HGNC:16352UniProt:Q9UI43
SLC25A4ADP/ATP translocase 1Disease-causing germline mutation(s) inModerado
VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 2

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
563.9 TPM
Coração - Átrio
428.0 TPM
Músculo esquelético
370.5 TPM
Cérebro - Hemisfério cerebelar
138.9 TPM
Esôfago - Muscular
110.1 TPM
OUTRAS DOENÇAS (5)
mitochondrial DNA depletion syndrome 12B (cardiomyopathic type), autosomal recessivemitochondrial DNA depletion syndrome 12A (cardiomyopathic type), autosomal dominantprogressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 2autosomal dominant progressive external ophthalmoplegia
HGNC:10990UniProt:P12235
PMS2Mismatch repair endonuclease PMS2Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (4)
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)TP53 Regulates Transcription of DNA Repair GenesDefective Mismatch Repair Associated With MLH1
MECANISMO DE DOENÇA

Lynch syndrome 4

A form of Lynch syndrome, an autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. Lynch syndrome is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, it is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical Lynch syndrome is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
22.4 TPM
Cérebro - Hemisfério cerebelar
17.8 TPM
Cerebelo
16.4 TPM
Fibroblastos
15.2 TPM
Skin Sun Exposed Lower leg
14.0 TPM
OUTRAS DOENÇAS (4)
mismatch repair cancer syndrome 4Lynch syndrome 4mismatch repair cancer syndromeLynch syndrome
HGNC:9122UniProt:P54278
MSH6DNA mismatch repair protein Msh6Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)Defective Mismatch Repair Associated With MSH2
MECANISMO DE DOENÇA

Lynch syndrome 5

A form of Lynch syndrome, an autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. Lynch syndrome is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, it is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical Lynch syndrome is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
40.1 TPM
Testículo
29.0 TPM
Útero
28.4 TPM
Linfócitos
26.3 TPM
Cervix Endocervix
21.9 TPM
OUTRAS DOENÇAS (5)
mismatch repair cancer syndrome 3Lynch syndrome 5Lynch syndromemismatch repair cancer syndrome
HGNC:7329UniProt:P52701
MVKMevalonate kinaseDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Lanosterol biosynthesisActivation of gene expression by SREBF (SREBP)
MECANISMO DE DOENÇA

Mevalonic aciduria

Accumulation of mevalonic acid which causes a variety of symptoms such as psychomotor retardation, dysmorphic features, cataracts, hepatosplenomegaly, lymphadenopathy, anemia, hypotonia, myopathy, and ataxia.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
41.6 TPM
Esôfago - Mucosa
40.7 TPM
Skin Sun Exposed Lower leg
34.1 TPM
Rim - Medula
33.4 TPM
Skin Not Sun Exposed Suprapubic
32.7 TPM
OUTRAS DOENÇAS (5)
mevalonic aciduriaporokeratosis 3, disseminated superficial actinic typehyperimmunoglobulinemia D with periodic feverporokeratosis of Mibelli
HGNC:7530UniProt:Q03426
KCNJ11ATP-sensitive inward rectifier potassium channel 11Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (6)
Ion homeostasisABC-family proteins mediated transportDefective ABCC9 causes CMD10, ATFB12 and Cantu syndromeDefective ABCC8 can cause hypo- and hyper-glycemiasRegulation of insulin secretion
MECANISMO DE DOENÇA

Hyperinsulinemic hypoglycemia, familial, 2

A form of hyperinsulinemic hypoglycemia, a clinically and genetically heterogeneous disorder characterized by inappropriate insulin secretion from the pancreatic beta-cells in the presence of low blood glucose levels. HHF2 is a common cause of persistent hypoglycemia in infancy. Unless early and aggressive intervention is undertaken, brain damage from recurrent episodes of hypoglycemia may occur. HHF2 inheritance can be autosomal dominant or autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
87.1 TPM
Cerebelo
37.4 TPM
Cérebro - Hemisfério cerebelar
36.8 TPM
Córtex cerebral
14.0 TPM
Brain Frontal Cortex BA9
13.9 TPM
OUTRAS DOENÇAS (12)
maturity-onset diabetes of the young type 13diabetes mellitus, permanent neonatal 2hyperinsulinemic hypoglycemia, familial, 2diabetes mellitus, transient neonatal, 3
HGNC:6257UniProt:Q14654
MLYCDMalonyl-CoA decarboxylase, mitochondrialDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Beta-oxidation of very long chain fatty acidsPeroxisomal protein import
MECANISMO DE DOENÇA

Malonyl-CoA decarboxylase deficiency

Autosomal recessive disease characterized by abdominal pain, chronic constipation, episodic vomiting, metabolic acidosis and malonic aciduria.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
13.3 TPM
Músculo esquelético
11.2 TPM
Coração - Átrio
10.1 TPM
Esôfago - Muscular
6.9 TPM
Esôfago - Junção
6.7 TPM
OUTRAS DOENÇAS (1)
malonic aciduria
HGNC:7150UniProt:O95822
PDX1Pancreas/duodenum homeobox protein 1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (5)
Regulation of gene expression in beta cellsRegulation of gene expression in early pancreatic precursor cellsDevelopmental Lineage of Multipotent Pancreatic Progenitor CellsDevelopmental Lineage of Pancreatic Ductal CellsDevelopmental Lineage of Pancreatic Acinar Cells
MECANISMO DE DOENÇA

Pancreatic agenesis 1

A disease characterized by isolated hypoplasia or agenesis of the pancreas, pancreatic beta-cell failure resulting in neonatal insulin-dependent diabetes mellitus, and exocrine pancreatic insufficiency.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pâncreas
9.2 TPM
Linfócitos
0.5 TPM
Testículo
0.2 TPM
Fígado
0.2 TPM
Estômago
0.1 TPM
OUTRAS DOENÇAS (6)
maturity-onset diabetes of the young type 4pancreatic agenesis 1pancreatic agenesismaturity-onset diabetes of the young
HGNC:6107UniProt:P52945
PLIN1Perilipin-1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (4)
Transcriptional regulation of white adipocyte differentiationMLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosisTriglyceride catabolismNR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose
MECANISMO DE DOENÇA

Lipodystrophy, familial partial, 4

An autosomal dominant form of lipodystrophy characterized by loss of subcutaneous adipose tissue primarily affecting the lower limbs, insulin-resistant diabetes mellitus, hypertriglyceridemia, and hypertension.

EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
970.2 TPM
Adipose Visceral Omentum
542.5 TPM
Mama
309.8 TPM
Nervo tibial
39.5 TPM
Artéria coronária
30.3 TPM
OUTRAS DOENÇAS (1)
PLIN1-related familial partial lipodystrophy
HGNC:9076UniProt:O60240
PRPH2Peripherin-2Disease-causing germline mutation(s) inTolerante
MECANISMO DE DOENÇA

Retinitis pigmentosa 7

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
9.3 TPM
Ovário
6.8 TPM
Cervix Ectocervix
5.7 TPM
Pituitária
5.3 TPM
Músculo esquelético
5.0 TPM
OUTRAS DOENÇAS (13)
retinitis pigmentosa 7vitelliform macular dystrophy 3fundus albipunctatuschoroidal dystrophy, central areolar 2
HGNC:9942UniProt:P23942
ASCC3Activating signal cointegrator 1 complex subunit 3Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
ALKBH3 mediated reversal of alkylation damage
MECANISMO DE DOENÇA

Intellectual developmental disorder, autosomal recessive 81

An autosomal recessive disorder characterized by variable features including mild to severe developmental delay, hypotonia, feeding difficulties, extreme fatigue, and neurobehavioral abnormalities.

OUTRAS DOENÇAS (1)
intellectual developmental disorder, autosomal recessive 81
HGNC:HGNC:18697UniProt:Q8N3C0
RUSC2AP-4 complex accessory subunit RUSC2Disease-causing germline mutation(s) inAltamente restrito
MECANISMO DE DOENÇA

Intellectual developmental disorder, autosomal recessive 61

A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRT61 patients manifest delayed psychomotor development, moderate to severe intellectual disability, and variable dysmorphic facial features. Refractory seizures and brain abnormalities are present in severely affected patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
112.9 TPM
Artéria tibial
112.5 TPM
Cerebelo
108.8 TPM
Cérebro - Hemisfério cerebelar
99.5 TPM
Córtex cerebral
78.6 TPM
OUTRAS DOENÇAS (1)
intellectual disability, autosomal recessive 61
HGNC:HGNC:23625UniProt:Q8N2Y8
GRIK2Glutamate receptor ionotropic, kainate 2Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (1)
Activation of Ca-permeable Kainate Receptor
MECANISMO DE DOENÇA

Intellectual developmental disorder, autosomal recessive 6

A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRT6 patients display mild to severe intellectual disability and psychomotor development delay in early childhood. Patients do not have neurologic problems, congenital malformations, or facial dysmorphism. Body height, weight, and head circumference are normal.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
95.5 TPM
Cerebelo
83.8 TPM
Hipotálamo
16.0 TPM
Brain Frontal Cortex BA9
14.5 TPM
Córtex cerebral
13.7 TPM
OUTRAS DOENÇAS (4)
intellectual disability, autosomal recessive 6neurodevelopmental disorder with impaired language and ataxia and with or without seizurescomplex neurodevelopmental disorderautosomal recessive non-syndromic intellectual disability
HGNC:4580UniProt:Q13002
IMPA1Inositol monophosphatase 1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Synthesis of IP2, IP, and Ins in the cytosol
MECANISMO DE DOENÇA

Intellectual developmental disorder, autosomal recessive 59

A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
33.7 TPM
Testículo
33.6 TPM
Tireoide
31.9 TPM
Brain Frontal Cortex BA9
20.1 TPM
Intestino delgado
19.9 TPM
OUTRAS DOENÇAS (2)
intellectual disability, autosomal recessive 59autosomal recessive non-syndromic intellectual disability
HGNC:6050UniProt:P29218
TRPM6Transient receptor potential cation channel subfamily M member 6Disease-causing germline mutation(s) inRestrito
VIAS BIOLÓGICAS (1)
TRP channels
MECANISMO DE DOENÇA

Hypomagnesemia 1

A disorder due to a primary defect in intestinal magnesium absorption. It is characterized by low levels of serum magnesium alongside with a normal renal magnesium secretion, secondary hypocalcemia and calcinocis. Affected individuals show neurologic symptoms of hypomagnesemic hypocalcemia, including seizures and muscle spasms, during infancy. Hypocalcemia is secondary to parathyroid failure resulting from magnesium deficiency. Untreated, the disorder may be fatal or may result in neurological damage.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Baixa expressão)
Brain Spinal cord cervical c-1
4.5 TPM
Testículo
3.0 TPM
Cólon transverso
2.6 TPM
Sangue
2.4 TPM
Substância negra
1.7 TPM
OUTRAS DOENÇAS (1)
intestinal hypomagnesemia 1
HGNC:17995UniProt:Q9BX84
DNAJC12DnaJ homolog subfamily C member 12Disease-causing germline mutation(s) inTolerante
MECANISMO DE DOENÇA

Hyperphenylalaninemia, mild, non-BH4-deficient

An autosomal recessive disorder characterized by increased serum phenylalanine, normal BH4 metabolism, and highly variable neurologic defects, including movement abnormalities and intellectual disability.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
94.7 TPM
Cerebelo
68.8 TPM
Pituitária
43.4 TPM
Glândula adrenal
36.3 TPM
Hipotálamo
30.1 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (1)
hyperphenylalaninemia due to DNAJC12 deficiency
HGNC:28908UniProt:Q9UKB3
MAT1AS-adenosylmethionine synthase isoform type-1Disease-causing germline mutation(s) inModerado
VIAS BIOLÓGICAS (3)
MethylationSulfur amino acid metabolismMetabolism of ingested SeMet, Sec, MeSec into H2Se
MECANISMO DE DOENÇA

Methionine adenosyltransferase deficiency

An inborn error of metabolism resulting in isolated hypermethioninemia. Most patients have no clinical abnormalities, although some neurologic symptoms may be present in rare cases with severe loss of methionine adenosyltransferase activity.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
749.3 TPM
Pâncreas
17.2 TPM
Testículo
16.7 TPM
Skin Sun Exposed Lower leg
9.0 TPM
Skin Not Sun Exposed Suprapubic
6.5 TPM
OUTRAS DOENÇAS (1)
methionine adenosyltransferase deficiency
HGNC:6903UniProt:Q00266
ADKAdenosine kinaseDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Purine salvageRibavirin ADME
MECANISMO DE DOENÇA

Hypermethioninemia due to adenosine kinase deficiency

A metabolic disorder characterized by global developmental delay, early-onset seizures, mild dysmorphic features, and characteristic biochemical anomalies, including persistent hypermethioninemia with increased levels of S-adenosylmethionine and S-adenosylhomocysteine. Homocysteine levels are typically normal.

OUTRAS DOENÇAS (1)
adenosine kinase deficiency
HGNC:257UniProt:P55263
APOBApolipoprotein B-100Disease-causing germline mutation(s) inRestrito
VIAS BIOLÓGICAS (8)
Platelet sensitization by LDLHeme signalingScavenging by Class B ReceptorsCell surface interactions at the vascular wallLDL remodeling
MECANISMO DE DOENÇA

Hypobetalipoproteinemia, familial, 1

A disorder of lipid metabolism characterized by less than 5th percentile age- and sex-specific levels of low density lipoproteins, and dietary fat malabsorption. Clinical presentation may vary from no symptoms to severe gastrointestinal and neurological dysfunction similar to abetalipoproteinemia.

OUTRAS DOENÇAS (3)
hypercholesterolemia, autosomal dominant, type Bfamilial hypobetalipoproteinemia 1homozygous familial hypercholesterolemia
HGNC:603UniProt:P04114
CA5ACarbonic anhydrase 5A, mitochondrialDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Reversible hydration of carbon dioxide
MECANISMO DE DOENÇA

Hyperammonemia due to carbonic anhydrase VA deficiency

An autosomal recessive inborn error of metabolism, clinically characterized by infantile hyperammonemic encephalopathy. Metabolic abnormalities include hypoglycemia, hyperlactatemia, metabolic acidosis and respiratory alkalosis.

INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency
HGNC:1377UniProt:P35218
BLOC1S3Biogenesis of lysosome-related organelles complex 1 subunit 3Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Golgi Associated Vesicle Biogenesis
MECANISMO DE DOENÇA

Hermansky-Pudlak syndrome 8

A form of Hermansky-Pudlak syndrome, a genetically heterogeneous autosomal recessive disorder characterized by oculocutaneous albinism, bleeding due to platelet storage pool deficiency, and lysosomal storage defects. This syndrome results from defects of diverse cytoplasmic organelles including melanosomes, platelet dense granules and lysosomes. Ceroid storage in the lungs is associated with pulmonary fibrosis, a common cause of premature death in individuals with HPS.

OUTRAS DOENÇAS (2)
Hermansky-Pudlak syndrome 8Hermansky-Pudlak syndrome 7
HGNC:20914UniProt:Q6QNY0
HFEHereditary hemochromatosis proteinDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Transferrin endocytosis and recycling
MECANISMO DE DOENÇA

Hemochromatosis 1

A disorder of iron metabolism characterized by iron overload. Excess iron is deposited in a variety of organs leading to their failure, and resulting in serious illnesses including cirrhosis, hepatomas, diabetes, cardiomyopathy, arthritis, and hypogonadotropic hypogonadism. Severe effects of the disease usually do not appear until after decades of progressive iron loading.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
15.7 TPM
Glândula adrenal
8.8 TPM
Baço
7.8 TPM
Aorta
6.6 TPM
Cervix Endocervix
6.5 TPM
OUTRAS DOENÇAS (6)
hemochromatosis type 1sporadic porphyria cutanea tardafamilial porphyria cutanea tardaobsolete symptomatic form of hemochromatosis type 1
HGNC:4886UniProt:Q30201
LBRDelta(14)-sterol reductase LBRDisease-causing germline mutation(s) inRestrito
VIAS BIOLÓGICAS (3)
Initiation of Nuclear Envelope (NE) ReformationCholesterol biosynthesis via desmosterol (Bloch pathway)Regulation of MECP2 expression and activity
MECANISMO DE DOENÇA

Pelger-Huet anomaly

An autosomal dominant inherited abnormality of granulocytes, characterized by abnormal ovoid shape, reduced nuclear segmentation and an apparently looser chromatin structure.

EXPRESSÃO TECIDUAL(Ubíquo)
Cólon sigmoide
89.3 TPM
Linfócitos
88.9 TPM
Útero
68.5 TPM
Esôfago - Muscular
63.1 TPM
Cervix Ectocervix
54.0 TPM
OUTRAS DOENÇAS (4)
Greenberg dysplasiaregressive spondylometaphyseal dysplasiaPelger-Huet anomalyReynolds syndrome
HGNC:6518UniProt:Q14739
PHKA2Phosphorylase b kinase regulatory subunit alpha, liver isoformDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (1)
Glycogen breakdown (glycogenolysis)
MECANISMO DE DOENÇA

Glycogen storage disease 9A

A metabolic disorder resulting in a mild liver glycogenosis with clinical symptoms that include hepatomegaly, growth retardation, muscle weakness, elevation of glutamate-pyruvate transaminase and glutamate-oxaloacetate transaminase, hypercholesterolemia, hypertriglyceridemia, and fasting hyperketosis. Two subtypes are known: type 1 or classic type with no phosphorylase kinase activity in liver or erythrocytes, and type 2 or variant type with no phosphorylase kinase activity in liver, but normal activity in erythrocytes. Unlike other glycogenosis diseases, glycogen storage disease type 9A is generally a benign condition. Patients improve with age and are often asymptomatic as adults. Accurate diagnosis is therefore also of prognostic interest.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
32.7 TPM
Pituitária
27.0 TPM
Fallopian Tube
25.7 TPM
Fígado
24.8 TPM
Útero
24.5 TPM
OUTRAS DOENÇAS (2)
glycogen storage disease IXa1glycogen storage disease due to liver phosphorylase kinase deficiency
HGNC:8926UniProt:P46019
GBA1Lysosomal acid glucosylceramidaseDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Gaucher disease

An autosomal recessive lysosomal storage disease due to deficient activity of lysosomal beta-glucocerebrosidase, and characterized by accumulation of glucosylceramide in the reticulo-endothelial system. GD is a multisystem disease historically divided into three main subtypes on the basis of the presence of neurologic involvement, age at onset and progression rate: type 1 is the non-neuropathic form, type 2 is the acute neuropathic form with early onset and rapid neurologic deterioration, type 3 is the chronic neuropathic form with slow progression of neurologic features. GD shows a marked phenotypic diversity ranging from adult asymptomatic forms, at the mild end, to perinatal lethal forms at the severe end of the disease spectrum. Formal diagnosis of Gaucher disease is based on the measurement of glucocerebrosidase levels in circulating leukocytes and molecular genetic analysis.

OUTRAS DOENÇAS (7)
Gaucher disease type IIGaucher disease perinatal lethalGaucher disease-ophthalmoplegia-cardiovascular calcification syndromeGaucher disease type I
HGNC:4177UniProt:P04062

Medicamentos e terapias

IBRUTINIBPhase 4

Mecanismo: Tyrosine-protein kinase BTK inhibitor

PATISIRAN SODIUMPhase 4

Mecanismo: Transthyretin mRNA RNAi inhibitor

VUTRISIRAN SODIUMPhase 4

Mecanismo: Transthyretin mRNA rnai inhibitor

SIMVASTATINPhase 4

Mecanismo: HMG-CoA reductase inhibitor

EZETIMIBEPhase 4

Mecanismo: Niemann-Pick C1-like protein 1 inhibitor

AMLODIPINE BESYLATEPhase 4

Mecanismo: Voltage-gated L-type calcium channel blocker

PITAVASTATIN CALCIUMPhase 4

Mecanismo: HMG-CoA reductase inhibitor

ALIROCUMABPhase 4

Mecanismo: Subtilisin/kexin type 9 inhibitor

EVOLOCUMABPhase 4

Mecanismo: Subtilisin/kexin type 9 inhibitor

EVINACUMABPhase 4

Mecanismo: Angiopoietin-related protein 3 inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

1.431 variantes patogênicas registradas no ClinVar.

🧬 FH: NM_000143.4(FH):c.1037G>C (p.Gly346Ala) ()
🧬 FH: NM_000143.4(FH):c.708del (p.Gln237fs) ()
🧬 FH: GRCh38/hg38 1q43-44(chr1:237818970-248924793)x1 ()
🧬 FH: NM_000143.4(FH):c.1462G>T (p.Glu488Ter) ()
🧬 FH: NM_000143.4(FH):c.422G>A (p.Trp141Ter) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

238 vias biológicas associadas aos genes desta condição.

Citric acid cycle (TCA cycle) Mitochondrial protein degradation Vitamin B1 (thiamin) metabolism Glycogen storage disease type Ia (G6PC) Gluconeogenesis FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Keratan sulfate degradation CS/DS degradation MPS IV - Morquio syndrome B (Keratin metabolism) Sialic acid metabolism Defective NEU1 causes sialidosis Neutrophil degranulation Glycosphingolipid catabolism MPS IV - Morquio syndrome B (CS/DS degradation) Lysine catabolism Purine salvage Sodium/Calcium exchangers Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6) Mitochondrial protein import Aspartate and asparagine metabolism Malate-aspartate shuttle Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation ATF4 activates genes in response to endoplasmic reticulum stress mRNA decay by 3' to 5' exoribonuclease Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA Major pathway of rRNA processing in the nucleolus and cytosol Nuclear RNA decay Glutamate and glutamine metabolism Proline catabolism GNAS1 GNAS2 GNAS G alpha (s):GTP:SRC dissociates G alpha (s):GTP:SRC catalyzes SRC to p-Y419-SRC G protein alpha (s):GTP binds SRC Interconversion of 2-oxoglutarate and 2-hydroxyglutarate Molybdenum cofactor biosynthesis Pre-NOTCH Processing in Golgi Keratan sulfate biosynthesis Interaction With Cumulus Cells And The Zona Pellucida Defective B4GALT1 causes B4GALT1-CDG (CDG-2d) Defective B4GALT1 causes CDG-2d Lactose synthesis N-Glycan antennae elongation TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway Antigen processing: Ubiquitination & Proteasome degradation SARS-CoV-2 modulates autophagy Formation of ATP by chemiosmotic coupling Mitochondrial translation termination Cristae formation Regulation of CDH11 Expression and Function Regulation of CDH11 gene transcription Intracellular oxygen transport Mitochondrial unfolded protein response (UPRmt) NADE modulates death signalling Activation of BIM and translocation to mitochondria Activation of caspases through apoptosome-mediated cleavage Ubiquinol biosynthesis Export of Viral Ribonucleoproteins from Nucleus NEP/NS2 Interacts with the Cellular Export Machinery Respiratory electron transport Complex I biogenesis Tryptophan catabolism OADH complex synthesizes glutaryl-CoA from 2-OA HS-GAG degradation MPS I - Hurler syndrome (HS-GAG degradation) MPS I - Hurler syndrome (CS/DS degradation) Post-translational modification: synthesis of GPI-anchored proteins ATP sensitive Potassium channels Regulation of insulin secretion Defective ABCC8 can cause hypo- and hyper-glycemias Nuclear signaling by ERBB4 Regulated proteolysis of p75NTR NRIF signals cell death from the nucleus Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants NOTCH2 Activation and Transmission of Signal to the Nucleus EPH-ephrin mediated repulsion of cells NOTCH3 Activation and Transmission of Signal to the Nucleus NOTCH4 Activation and Transmission of Signal to the Nucleus Noncanonical activation of NOTCH3 Amyloid fiber formation TGFBR3 PTM regulation RHOA GTPase cycle Mitochondrial translation initiation Mitochondrial translation elongation Mitochondrial ribosome-associated quality control Mitochondrial tRNA aminoacylation Degradation of GABA 3-Methylcrotonyl-CoA carboxylase deficiency Transcriptional regulation by RUNX2 Signaling by NOTCH2 Response of endothelial cells to shear stress Developmental Cell Lineages TP53 Regulates Transcription of Cell Death Genes SARS-CoV-2 Infection Downregulation of ERBB2 signaling Regulation of CDH1 Expression and Function Regulation of RUNX2 expression and activity Transcriptional activation of mitochondrial biogenesis Strand-asynchronous mitochondrial DNA replication Defective MUTYH substrate processing Defective Base Excision Repair Associated with NEIL1 Signaling by MET Virion Assembly and Release Virion Assembly and Release IKK complex recruitment mediated by RIP1 Transcriptional regulation by RUNX1 Regulation of gene expression in beta cells Insulin processing Synthesis, secretion, and deacylation of Ghrelin COPI-mediated anterograde transport PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling NPAS4 regulates expression of target genes MPS II - Hunter syndrome (HS-GAG degradation) MPS II - Hunter syndrome (CS/DS degradation) Peroxisomal protein import p75NTR recruits signalling complexes NF-kB is activated and signals survival PINK1-PRKN Mediated Mitophagy Neddylation Interleukin-1 signaling Pexophagy Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Nuclear events mediated by NFE2L2 Processing of SMDT1 LDL clearance Coenzyme A biosynthesis Scavenging by Class A Receptors Golgi Associated Vesicle Biogenesis Iron uptake and transport Serine metabolism Myoclonic epilepsy of Lafora Defective ALG2 causes CDG-1i Defective ALG14 causes ALG14-CMS Non-integrin membrane-ECM interactions ECM proteoglycans Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 DAG1 core M2 glycosylations DAG1 core M3 glycosylations DAG1 core M1 glycosylations Regulation of expression of SLITs and ROBOs EGR2 and SOX10-mediated initiation of Schwann cell myelination Formation of the dystrophin-glycoprotein complex (DGC) Matriglycan biosynthesis on DAG1 Glycogen breakdown (glycogenolysis) The activation of arylsulfatases Attachment of GPI anchor to uPAR MPS IIIC - Sanfilippo syndrome C Hyaluronan degradation MPS VII - Sly syndrome (Hyaluronan metabolism) MPS VII - Sly syndrome (CS/DS degradation) TP53 Regulates Metabolic Genes Cytoprotection by HMOX1 Complex IV assembly Heme biosynthesis Maturation of TCA enzymes and regulation of TCA cycle rRNA modification in the mitochondrion Mitochondrial Uncoupling Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) Defective Mismatch Repair Associated With MLH1 Defective Mismatch Repair Associated With PMS2 TP53 Regulates Transcription of DNA Repair Genes Defective Mismatch Repair Associated With MSH2 Defective Mismatch Repair Associated With MSH6 Activation of gene expression by SREBF (SREBP) Lanosterol biosynthesis ABC-family proteins mediated transport Ion homeostasis Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome Beta-oxidation of very long chain fatty acids Regulation of gene expression in early pancreatic precursor cells Developmental Lineage of Pancreatic Acinar Cells Developmental Lineage of Pancreatic Ductal Cells Developmental Lineage of Multipotent Pancreatic Progenitor Cells Triglyceride catabolism Transcriptional regulation of white adipocyte differentiation NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis ALKBH3 mediated reversal of alkylation damage ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA Activation of Na-permeable kainate receptors Activation of Ca-permeable Kainate Receptor Synthesis of IP2, IP, and Ins in the cytosol TRP channels CREB3L4 translocates from the cytosol to the nucleus Methylation Sulfur amino acid metabolism Metabolism of ingested SeMet, Sec, MeSec into H2Se Defective MAT1A causes MATD Ribavirin ADME Cell surface interactions at the vascular wall Scavenging by Class B Receptors Scavenging by Class F Receptors Scavenging by Class H Receptors Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Platelet sensitization by LDL Regulation of TLR by endogenous ligand Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis VLDL assembly Post-translational protein phosphorylation Chylomicron assembly Chylomicron remodeling Chylomicron clearance LDL remodeling VLDL clearance Heme signaling Retinoid metabolism and transport Reversible hydration of carbon dioxide Transferrin endocytosis and recycling Cholesterol biosynthesis via desmosterol (Bloch pathway) RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOG GTPase cycle RAC3 GTPase cycle Regulation of MECP2 expression and activity Association of TriC/CCT with target proteins during biosynthesis

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado10
3Fase 311
2Fase 223
1Fase 18
·Pré-clínico58
Medicamentos catalogadosEnsaios clínicos· 10 medicamentos · 100 ensaios
✓ Aprovados — podem ser usados hoje
IBRUTINIBPATISIRAN SODIUMVUTRISIRAN SODIUMSIMVASTATINEZETIMIBEAMLODIPINE BESYLATEPITAVASTATIN CALCIUMALIROCUMABEVOLOCUMABEVINACUMAB
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Erros congênitos do metabolismo raros

Centros de Referência SUS

21 centros habilitados pelo SUS para Erros congênitos do metabolismo raros

Centros para Erros congênitos do metabolismo raros

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

NUPAD / Faculdade de Medicina UFMG

Av. Prof. Alfredo Balena, 189 - 5 andar - Centro, Belo Horizonte - MG, 30130-100 · CNES 2183226

Serviço de Referência

Rota
Erros Inatos do Metabolismo

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da Universidade Federal de Pernambuco

Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife - PE, 50670-901 · CNES 2561492

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Onofre Lopes (HUOL)

Av. Nilo Peçanha, 620 - Petrópolis, Natal - RN, 59012-300 · CNES 2408570

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Instituto da Criança e do Adolescente (ICr-HCFMUSP)

Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo - SP, 05403-000 · CNES 2081695

Serviço de Referência

Rota
Erros Inatos do Metabolismo

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 17 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

16 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07473843 · Study of Zodasiran in Adolescent Participants With Homozygou…Recrutando
PHASE3🇩🇰 Dinamarca · 🇺🇸 Estados Unidos
NCT07615400 · A Long-Term Observational Study of Patients With FucosidosisRecrutando
🇮🇳 Índia · 🇳🇱 Países Baixos · Tunisia +3
NCT07837336 · An Evaluation of Nutritional Status, Body Composition, and D…Recrutando
Philippines
NCT06839456 · Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Vira…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT06805695 · Long-term Follow-up (LTFU) Study of Participants in Any iECU…Recrutando
🇬🇧 Reino Unido · 🇺🇸 Estados Unidos
NCT06729554 · Education & Care in RARE: Efficacy of Targeted Psychoeducati…Recrutando
NA🇦🇹 Áustria
NCT06337864 · Effect of Large Neutral Amino Acids in Adults With Classical…Recrutando
NA🇩🇰 Dinamarca
NCT06360913 · Blood Spot and Urine Metabolomic Screening Applied to Rare D…Recrutando
NA🇧🇪 Bélgica
NCT05619900 · Registry of Patients Diagnosed With Lysosomal Storage Diseas…Recrutando
🇺🇸 Estados Unidos
NCT05295433 · An Extension Study to Evaluate the Long-Term Safety and Clin…Recrutando
PHASE1, PHASE2🇨🇦 Canadá · 🇫🇷 França · 🇳🇱 Países Baixos +3
NCT05130437 · A Study to Assess the Long-term Safety and Clinical Activity…Recrutando
PHASE1, PHASE2🇨🇦 Canadá · 🇫🇷 França · 🇯🇵 Japão +5
NCT04159103 · Open-Label Study of mRNA-3927 in Participants With Propionic…Recrutando
PHASE1, PHASE2🇨🇦 Canadá · 🇫🇷 França · 🇯🇵 Japão +5
NCT02890342 · Natural History, Physiology, Microbiome and Biochemistry Stu…Recrutando
🇺🇸 Estados Unidos
NCT02356653 · Expanded Access Protocol Using CD3+/CD19+ Depleted PBSCRecrutando
EARLY_PHASE1🇺🇸 Estados Unidos
NCT00078078 · Clinical and Laboratory Study of Methylmalonic AcidemiaRecrutando
🇺🇸 Estados Unidos
NCT00005909 · Study of AlkaptonuriaRecrutando
🇺🇸 Estados Unidos

Outros ensaios clínicos

153 ensaios clínicos encontrados, 24 ativos.

Distribuição por fase
NCT07818759 · Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients Wit…Em breve
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07802366 · Market Research of a Slow Release Protein Substitute for the…Em breve
NA🇬🇧 Reino Unido
NCT07704606 · Metabolites in Blood and Breath in Metabolic ConditionsEm breve
NCT06654765 · Growth and Development of Children With Inborn Errors of Met…Em breve
🇪🇬 Egito
NCT07619170 · EasiVits Acceptability & Tolerance StudyAtivo
NA🇬🇧 Reino Unido
NCT07226622 · Prescreening Study to Identify Potential Wilson Disease Part…Ativo
🇺🇸 Estados Unidos
NCT06255782 · An Open-label Study to Investigate ECUR-506 in Male Babies L…Ativo
PHASE3🇦🇺 Austrália · 🇪🇸 Espanha · 🇬🇧 Reino Unido +1
NCT05739643 · Gene Transfer Clinical Trial for Infantile and Late Infantil…Ativo
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT02112994 · Safety and Efficacy Study of Sebelipase Alfa in Participants…Concluído
PHASE2🇧🇷 Brasil · 🇦🇺 Austrália · 🇧🇪 Bélgica +12
NCT00694109 · An Open-label Extension Study to Assess the Long-term Safety…Concluído
PHASE3🇧🇷 Brasil · 🇨🇦 Canadá · Singapore +4
NCT00607373 · Study to Assess the Safety and Efficacy of ISIS 301012 (Mipo…Concluído
PHASE3🇧🇷 Brasil · 🇨🇦 Canadá · Singapore +4
NCT05732922 · ORCHARD- Optimising Home Assessment of Rural PatientsConcluído
NA🇬🇧 Reino Unido
NCT05818566 · Orphan Drugs for Inherited Metabolic DiseasesConcluído
🇨🇭 Suíça
NCT05462132 · Safety, Tolerability and Pharmacodynamics of SYNB1353 in Hea…Concluído
PHASE1🇺🇸 Estados Unidos
NCT05330039 · Characterization of Intestinal Microbiota in Children With I…Concluído
🇨🇭 Suíça
NCT04999566 · Cardiac Manifestation and Inherited Metabolic DiseasesConcluído
🇨🇭 Suíça
NCT05123768 · Genetic Etiology in Patients With Cerebral PalsyConcluído
Slovenia
NCT04399694 · Identification and Characterization of Novel Non-Coding Vari…Concluído
🇺🇸 Estados Unidos
NCT04201418 · A Multicenter Observational Study to Evaluate the Effectiven…Concluído
🇺🇸 Estados Unidos
NCT04098198 · Biomarkers for Inborn Errors of MetabolismConcluído
Albania · 🇪🇬 Egito · Georgia +5
NCT05437445 · Utilizing Augmented Artificial Intelligence for Aminoacidopa…Concluído
Pakistan
NCT04248062 · Patient and Observer Reported Outcome Measurements in Inborn…Concluído
🇨🇭 Suíça
NCT03620071 · GoalKeeper: Intelligent Information Sharing for Children Wit…Concluído
NA🇺🇸 Estados Unidos
NCT04318509 · Market Research - Acceptability Study for a New PKU Protein …Concluído
NA🇬🇧 Reino Unido
NCT03548779 · North Carolina Genomic Evaluation by Next-generation Exome S…Concluído
NA🇺🇸 Estados Unidos
NCT04309331 · Market Research - Acceptability Trial for a New PKU Amino Ac…Concluído
NA🇬🇧 Reino Unido
NCT03350451 · An Extension Study of an Investigational Drug, Lumasiran (AL…Concluído
PHASE2🇫🇷 França · 🇩🇪 Alemanha · 🇮🇱 Israel +2
NCT03534752 · Retrospective Study of Adult Patients With Inborn Errors of …Concluído
🇨🇭 Suíça
NCT03484767 · "The MaP Study": Mapping the Patient Journey in MMA and PAConcluído
🇫🇷 França · 🇪🇸 Espanha · 🇬🇧 Reino Unido +1
NCT04709965 · Evaluating Face-Recognition Technology in Syndrome DiagnosisConcluído
NA🇬🇧 Reino Unido
NCT03360747 · Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Particip…Concluído
PHASE2🇨🇦 Canadá
NCT03233841 · Farber Disease Natural History StudyConcluído
🇦🇷 Argentina · 🇨🇦 Canadá · 🇪🇬 Egito +6
NCT03168399 · Evaluation of PKU ExploreConcluído
NA🇬🇧 Reino Unido
NCT03609840 · Study of Thiotepa and TEPA Drug Exposure in Pediatric Hemato…Concluído
🇺🇸 Estados Unidos
NCT03058848 · Evaluation of PKU StartConcluído
NA🇬🇧 Reino Unido
NCT02826694 · North Carolina Newborn Exome Sequencing for Universal Screen…Concluído
NA🇺🇸 Estados Unidos
NCT03609814 · Study of Clofarabine and Fludarabine Drug Exposure in Pediat…Concluído
🇺🇸 Estados Unidos
NCT03609827 · Study of Melphalan Drug Exposure in Pediatric Hematopoietic …Concluído
🇺🇸 Estados Unidos
NCT02349906 · Treosulfan-based Versus Busulfan-based Conditioning in Paedi…Concluído
PHASE2🇨🇿 Tchéquia · 🇩🇪 Alemanha · 🇮🇹 Itália +1
NCT02324049 · Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of S…Concluído
PHASE1, PHASE2🇪🇸 Espanha · 🇬🇧 Reino Unido · 🇺🇸 Estados Unidos
NCT02322177 · Maternal Inborn Errors of Metabolism in Pregnancy: A Pregnan…Concluído
🇺🇸 Estados Unidos
NCT02056912 · Identification of a New Gene Involved in Hereditary Lipodyst…Concluído
NA🇫🇷 França
NCT02090179 · Evaluation of Blood Brain Barrier Integrity and Structural A…Concluído
🇬🇧 Reino Unido
NCT03911089 · A Collection of Case Studies in Infants With UCD to Evaluate…Concluído
NA🇺🇸 Estados Unidos
NCT01586455 · Human Placental-Derived Stem Cell TransplantationConcluído
PHASE1🇺🇸 Estados Unidos
NCT01498263 · Inherited Diseases, Caregiving, and Social NetworksConcluído
🇺🇸 Estados Unidos
NCT01049854 · CD34+Selection for Partially Matched Family or Matched Unrel…Concluído
PHASE2🇺🇸 Estados Unidos
NCT01432561 · Study in Healthy Adults to Determine the Effect That Food Ha…Concluído
NA🇺🇸 Estados Unidos
NCT01316549 · Study of Fludarabine Drug Exposure in Pediatric Bone Marrow …Concluído
🇺🇸 Estados Unidos
NCT00919503 · Treosulfan and Fludarabine Phosphate Before Donor Stem Cell …Concluído
PHASE2🇺🇸 Estados Unidos
NCT00958438 · PREventative Study Against URate-Lowering Drug-Induced Gout …Concluído
PHASE3🇩🇪 Alemanha · 🇮🇳 Índia · Indonesia +2
NCT00855920 · Study Utilizing Rilonacept in Gout ExacerbationsConcluído
PHASE3🇺🇸 Estados Unidos
NCT00856206 · Review of Safety Using Rilonacept in Preventing Gout Exacerb…Concluído
PHASE3🇩🇪 Alemanha · 🇮🇳 Índia · Indonesia +3
NCT00829829 · PREventative Study Against URate-lowering Drug-induced Gout …Concluído
PHASE3🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT00744692 · Reduced Intensity Conditioning for Umbilical Cord Blood Tran…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00477594 · Open Label Extension of ISIS 301012 (Mipomersen) to Treat Fa…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00383448 · HSCT for High Risk Inherited Inborn ErrorsConcluído
PHASE2🇺🇸 Estados Unidos
NCT00362180 · Measure Liver Fat Content After ISIS 301012 (Mipomersen) Adm…Concluído
PHASE2🇳🇱 Países Baixos
NCT00351156 · Study to Evaluate Blood Cell Lines From Patients With Gauche…Concluído
🇺🇸 Estados Unidos
NCT00328159 · Nutritional Therapy of the Deficits of Oxidation Mitochondri…Concluído
NA🇫🇷 França
NCT00309400 · The Early History of Universal Screening for Metabolic Disor…Concluído
🇺🇸 Estados Unidos
NCT00692926 · Unrelated Umbilical Cord Blood Transplantation Augmented Wit…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00001596 · Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pud…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00099996 · Higher-Dose Ezetimibe to Treat Homozygous SitosterolemiaConcluído
PHASE3🇺🇸 Estados Unidos
NCT00176891 · Stem Cell Transplant w/Laronidase for HurlerConcluído
PHASE2🇺🇸 Estados Unidos
NCT00005103 · Study of the Pathogenesis of Porphyria Cutanea TardaConcluído
🇺🇸 Estados Unidos
NCT00010361 · Study of Total Body Irradiation and Fludarabine Followed By …Concluído
NA🇺🇸 Estados Unidos
NCT00006061 · Study of Phosphatidylcholine in a Patient With Methionine Ad…Concluído
NA
NCT00006057 · Diagnostic and Screening Study of Genetic DisordersConcluído
🇺🇸 Estados Unidos
NCT00004294 · Phase I Study of Retrovirally Mediated Transfer of the Human…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00004481 · Genetic Study of SitosterolemiaConcluído
🇺🇸 Estados Unidos
NCT00004490 · Phase III Randomized Study of Sodium Dichloroacetate in Chil…Concluído
PHASE3
NCT00004488 · Phase II Randomized Study of Alendronate Sodium for Osteopen…Concluído
PHASE2🇮🇱 Israel · 🇺🇸 Estados Unidos
NCT00004443 · Study of NTBC for Tyrosinemia IConcluído
NA🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT00004493 · Phase II Pilot Randomized Study of Sodium Dichloroacetate in…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00004450 · Randomized Study of Beta Interferon and Thalidomide in Patie…Concluído
NA
NCT00004398 · Phase I Study of Heme Arginate With or Without Tin Mesoporph…Concluído
PHASE1
NCT00004397 · Phase I Study of Tin Mesoporphyrin in Patients on Long Term …Concluído
PHASE1
NCT00004396 · Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acut…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00004831 · Study of Cysteine Hydrochloride for Erythropoietic Protoporp…Concluído
NA
NCT00004454 · Phase I/II Study of Retroviral-Mediated Transfer of Iduronat…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT00004940 · Phase III Study of L-Cysteine in Patients With Erythropoieti…Concluído
PHASE3
NCT00004314 · Phase II Pilot Study of Aminoimidazole Carboxamide Riboside …Concluído
PHASE2
NCT00004770 · Pilot Compassionate Use Study of Thioctic Acid Treatment in …Concluído
NA
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Erros congênitos do metabolismo raros.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Erros congênitos do metabolismo raros e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

São distúrbios hereditários causados por falhas enzimáticas que afetam o metabolismo de nutrientes como proteínas, gorduras e carboidratos, além de organelas celulares. Eles recebem a classificação internacional CID-10 E90 e código Orpha 68367.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

6 publicações do grafo RarasNet (PubMed) · 7 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. Screening of Newborns for Disorders with High Benefit-Risk Ratios Should Be Mandatory.
    The Journal of law, medicine &amp; ethics : a journal of the American Society of Law, Medicine &amp; Ethics2016PMID 27338599
  2. ORPHA:68367
    Orphanet
  3. GARD:22508
    GARD (NIH)
  4. Q1758393
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Erros congênitos do metabolismo raros. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/erros-congenitos-do-metabolismo-raros

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Erros congênitos do metabolismo raros
Compêndio · Raras BR

Erros congênitos do metabolismo raros

ORPHA:68367 · MONDO:0019052
Prevalência
1-9 / 100 000
CID-10
E90 · Transtornos nutricionais e metabólicos em doenças classificadas em outra parte
Ensaios
24 ativos
Medicamentos
19 registrados
Prevalência
3.3 (Germany)
MedGen
UMLS
C0025521
EuropePMC
Wikidata
Wikipedia

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Moléculas estudadas na doença
fonte: OpenTargets
Rara